Trials / Terminated
TerminatedNCT05737186
SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency
The Efficacy and Safety of SGLT2 Inhibitors in Improving Heart Failure in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) and Severe Renal Insufficiency
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In the treatment of heart failure (HF), SGLT-2 inhibitor (SGLT-2i) can significantly improve the clinical outcome and quality of life related to HF. The current data show that SGLT-2i is effective and safe in improving HF outcomes in patients with chronic kidney disease (CKD) stage 4, but there is little clinical evidence in patients with eGFR\<20 ml/min/1.73 m2. Therefore, our research is designed to confirm that SGLT-2i can improve the outcome of HF in patients with chronic heart failure with reduced ejection fraction (HFrEF) and severe chronic renal insufficiency (eGFR\<20ml/min/1.73m2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGLT-2 inhibitor | dapagliflozin |
Timeline
- Start date
- 2023-03-09
- Primary completion
- 2024-04-16
- Completion
- 2024-04-16
- First posted
- 2023-02-21
- Last updated
- 2024-04-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05737186. Inclusion in this directory is not an endorsement.